|MDACC Study No:||2013-0225 (clinicaltrials.gov NCT No: NCT01893372)|
|Title:||Phase II Study of Eltrombopag With or Without Continuation of Hypomethylating Agent After Hypomethylating Agent Failure For Patients with MDS|
|Principal Investigator:||Courtney DiNardo|
|Treatment Agent:||Azacitidine; Decitabine; Eltrombopag|
|Study Description:||The goal of this clinical research study is to learn if eltrombopag can help to |
control MDS. The safety of this drug will also be studied.